Concepedia

Laurence Chu

LC

Statistics

Publications

26

Citations

1.7K

H-Index

16

Active since

1994

Affiliations

Benchmark Research (United States)(Current)

Moderna Therapeutics (United States)

Meridian Clinical Research

GlaxoSmithKline (Belgium)

Baylor College of Medicine

Laurence Chu is an author at Benchmark Research (United States) specializing in vaccination, vaccinology, and immunization.

ORCID

Publications per year

1994–2023

26

Publications

26

Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis

Angela Choi, Matthew Koch, Laurence Chu et al. · Nature Medicine · 2021 · 449 citations · Full text

, , +17

A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine

Laurence Chu, Roderick McPhee, Wenmei Huang et al. · Vaccine · 2021 · 237 citations · Full text

, , +17

The safety and immunogenicity of two Zika virus mRNA vaccine candidates in healthy flavivirus baseline seropositive and seronegative adults: the results of two randomised, placebo-controlled, dose-ranging, phase 1 clinical trials

Brandon Essink, Laurence Chu, William Seger et al. · The Lancet Infectious Diseases · 2023 · 141 citations

, , +15

Safety and immunogenicity of the rVSV∆G-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response study

D. Gray Heppner, Tracy Kemp, Brian K. Martin et al. · The Lancet Infectious Diseases · 2017 · 121 citations · Full text

, , +14

Immune response to SARS-CoV-2 after a booster of mRNA-1273: an open-label phase 2 trial

Laurence Chu, Keith Vrbicky, David C. Montefiori et al. · Nature Medicine · 2022 · 104 citations · Full text

, , +17

1–5 of 26